| GTO ID | GTC0944 |
| Trial ID | ChiCTR2100050521 |
| Disease | Nasopharyngeal Carcinoma |
| Altered gene | EBV |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | EBV TCR-T cells |
| HLA | HLA-A*11:01|HLA-A*02:01|HLA-A*24:02 |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | A clinical study on the safety and preliminary effectiveness of EBV TCR-T cells in the treatment of patients with relapsed/refractory EBV-positive nasopharyngeal carcinoma |
| Year | 2021 |
| Country | China |
| Company sponsor | Affiliated Hospital of Xuzhou Medical University |
| Cohort 1 | |||||||
|
|||||||